Cardiovascular Disease pp 323-326 | Cite as
Studies of Apolipoprotein B And Lipoprotein(a) in Transgenic Mice
Summary
Two of the many differences in lipoprotein metabolism between mice and humans are a predominance of high density lipoproteins (HDL) in mice compared with high levels of low density lipoproteins (LDL) in humans, and the lack of either apolipoprotein(a) (apo[a]) or lipoprotein(a) (Lp[a]) in the mouse. In order to develop a strain of mice with higher levels of LDL and with Lp(a), a Pl phagemid library was screened for a human apoB genomic clone. A clone containing the entire human apoB gene was isolated and used to create multiple lines of mice expressing high levels of human apoB. The lipoproteins of the human apoB transgenic animals differed from control mice due to the presence of significant amounts of low-density lipoprotein particles containing human apoB1. The human apoB transgenic mice were crossed with a previously described line of transgenic mice expressing human apo(a) cDNA2. The resulting combined transgenic animals expressing both human apoB and human apo(a) produced an Lp(a) particle sharing many properties with Lp(a) present in the plasma of humans. The present series of transgenic animals will serve as useful substrates to address issues relevant to LDL and Lp(a) that are difficult to approach in either humans or naturally occurring animal models.
Keywords
Transgenic Mouse High Density Lipoprotein Cholesteryl Ester Transfer Protein Lipoprotein Metabolism Human ApolipoproteinPreview
Unable to display preview. Download preview PDF.
References
- 1.M.J. Callow, L.J. Stoltzfus, R.M. Lawn, & E.M Rubin, Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice, Proc. Nat’l Acad. Sci. USA 92:21130–21136 (1994).Google Scholar
- 2.G. Chiesa, Expression of human apolipoprotein B100 in transgenic mice, J Bio Chem 268:23747–23750 (1993).Google Scholar
- 3.E.M. Rubin, & D.J. Smith, Getting to the heart of a polygenic disorder: atherosclerosis in mice, Trend Gen (submitted, 1994).Google Scholar
- 4.J.L. Breslow, Transgenic mouse models of lipoprotein metabolism and atherosclerosis, Proc Natl Acad Sci, USA 90:8314–8318 (1993).PubMedCrossRefGoogle Scholar
- 5.G. Chiesa, et al., Reconstitution of lipoprotein (a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein (a), J Biol Chem 267:24369–24374 (1992).PubMedGoogle Scholar
- 6.J.W. Gaubatz, C. Heideman, A.M.J. Gotto, J.D. Morrisett, G.H. Dahlen, Human plasma lipoprotein(a); structural properties, J Bio Chem 258:4582–4589 (1983).Google Scholar
- 7.G. Utermann, W. Weber, Protein composition of Lp(a) lipoprotein from human plasma, FEBS Let 154:357–361 (1983).CrossRefGoogle Scholar
- 8.J.J. Guevara et al., Proposed mechanisms for binding of apo(a) kringle type 9 to apo B-100 in human lipoprotein(a), Biophys J 64:686–700 (1993).PubMedCrossRefGoogle Scholar
- 9.R.M. Lawn, et al., Atherogenesis in transgenic mice expressing human apolipoprotein (a). Nature, 360:670–672 (1992).PubMedCrossRefGoogle Scholar
- 10.M.F. Linton, et al., Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a), J Clin Invest 92:3029–3037 (1993).PubMedCrossRefGoogle Scholar
- 11.A. Walsh, et al., Intestinal expression of the human apoA-I gene in transgenic mice is controlled by a DNA region 3’ to the gene in the promoter of the adjacent convergently transcribed apoC-III gene, J. Lipid. Res. 34:617–623 (1993).PubMedGoogle Scholar